Chen-Yueh Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chen-Yueh Wen has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Jung Li
Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital , Kaohsiung
7 shared publications - Jen-Tai Lin
Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
4 shared publications - Su-Boon Yong
Department of Allergy and Immunology China Medical University Children Hospital Taichung Taiwan
4 shared publications Chia-Cheng Yu
Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
2 shared publications- Chia-Cheng Yu
Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
2 shared publications - Meng-Yu Wu
Department of Emergency Medicine, Taipei Tzu Chi Hospital, New Taipei, Taiwan
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Springer Nature in Journal of Translational Medicine
Reproducibility-driven clinical translation of spatial multi-omics in precision medicine
- 16 September 2026
- Published by Springer Nature in Journal of Translational Medicine
Open AccessReproducibility-driven clinical translation of spatial multi-omics in precision medicine
- 18 May 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (6) , 145
The GPX1-OSBPL8 axis: integrating ER ferroptosis and apoptotic signaling
The classification of regulated cell death (RCD) has evolved from discrete, siloed pathways into an integrated network of metabolic and proteostatic checkpoints. For over a decade, the glutathione peroxidase 4 (GPX4)-dependent neutralization of lipid hydroperoxides on the plasma membrane was considered the primary defense against ferroptosis. However, the landmark discovery by Xia et al. [1] in Cell has identified a “non-canonical” ferroptosis pathway governed by the GPX1-OSBPL8 axis, which operates specifically at the endoplasmic reticulum (ER). By elucidating how the lipid transfer protein OSBPL8 recruits GPX1 to reduce peroxidized phosphatidic acid (PA-OOH), this research provides a definitive organelle-specific mechanism for lipid-driven cell death. For the field of apoptosis, this discovery is pivotal: it positions the ER as a central decision-making hub where ferroptotic lipid damage converges with intrinsic apoptotic signals via ER stress, the Unfolded Protein Response (UPR), and unregulated calcium dynamics. This commentary evaluates the mechanistic underpinnings of this non-canonical axis and explores the synergistic potential of targeting ER-localized death programs in oncology.
- 18 May 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (6) , 145
The GPX1-OSBPL8 axis: integrating ER ferroptosis and apoptotic signaling
The classification of regulated cell death (RCD) has evolved from discrete, siloed pathways into an integrated network of metabolic and proteostatic checkpoints. For over a decade, the glutathione peroxidase 4 (GPX4)-dependent neutralization of lipid hydroperoxides on the plasma membrane was considered the primary defense against ferroptosis. However, the landmark discovery by Xia et al. [1] in Cell has identified a “non-canonical” ferroptosis pathway governed by the GPX1-OSBPL8 axis, which operates specifically at the endoplasmic reticulum (ER). By elucidating how the lipid transfer protein OSBPL8 recruits GPX1 to reduce peroxidized phosphatidic acid (PA-OOH), this research provides a definitive organelle-specific mechanism for lipid-driven cell death. For the field of apoptosis, this discovery is pivotal: it positions the ER as a central decision-making hub where ferroptotic lipid damage converges with intrinsic apoptotic signals via ER stress, the Unfolded Protein Response (UPR), and unregulated calcium dynamics. This commentary evaluates the mechanistic underpinnings of this non-canonical axis and explores the synergistic potential of targeting ER-localized death programs in oncology.
- Open Access
- 6 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119103
Mitoxyperilysis links organelle positioning to inflammatory lysis: A new lens for pharmacotherapy design
- 6 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119103
Open AccessMitoxyperilysis links organelle positioning to inflammatory lysis: A new lens for pharmacotherapy design
- Open Access
- 4 March 2025
- Published by Elsevier in Pharmacological Research
- Vol. 214, 107684
Targeting EVA1B in breast cancer: New avenues for precision oncology
- 4 March 2025
- Published by Elsevier in Pharmacological Research
- Vol. 214, 107684
Open AccessTargeting EVA1B in breast cancer: New avenues for precision oncology
- Open Access
- 18 July 2024
- Published by Elsevier in Pharmacological Research
- Vol. 207, 107320
The dual role of NSD2 in mitochondrial function: Insights into interstitial fibrosis and renal cancer
- 18 July 2024
- Published by Elsevier in Pharmacological Research
- Vol. 207, 107320
Open AccessThe dual role of NSD2 in mitochondrial function: Insights into interstitial fibrosis and renal cancer
- Open Access
- 28 May 2024
- Published by Elsevier in Pharmacological Research
- Vol. 205, 107241
ACOX1 in cancer and immunity: Unraveling its complex interplay
- 28 May 2024
- Published by Elsevier in Pharmacological Research
- Vol. 205, 107241
Open AccessACOX1 in cancer and immunity: Unraveling its complex interplay
- Open Access
- 29 April 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (8) , 3712-3713
Robot-assisted transabdominal preperitoneal approach for inguinal hernioplasty using Hugo RAS system: The first case report in Asia
- 29 April 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (8) , 3712-3713
Open AccessRobot-assisted transabdominal preperitoneal approach for inguinal hernioplasty using Hugo RAS system: The first case report in Asia
- Open Access
Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review
Currently, medication for benign prostate hyperplasia (BPH) and prostate cancer (PCa) are mainly based on modulating the hormone and nervous systems. However, side effects often affect patients, and might decrease their commitment to continuing the medication and lower their quality of life. Some studies have indicated that chronic inflammation might be the cause of BPH and PCa. Based on this hypothesis, the effect of phloretin, a potent anti-inflammatory and anti-oxidative flavonoid, has been researched since 2010. Results from animal and in-vitro studies, obtained from databases, also indicate that the use of phloretin in treating BPH and PCa is promising. Due to its effect on inflammatory cytokines, apoptosis or anti-apoptosis, reactive oxygen species, anti-oxidant enzymes and oxidative stress, phloretin is worthy of further study in human clinical trials regarding safety and effective dosages.
Open AccessPhloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review
Currently, medication for benign prostate hyperplasia (BPH) and prostate cancer (PCa) are mainly based on modulating the hormone and nervous systems. However, side effects often affect patients, and might decrease their commitment to continuing the medication and lower their quality of life. Some studies have indicated that chronic inflammation might be the cause of BPH and PCa. Based on this hypothesis, the effect of phloretin, a potent anti-inflammatory and anti-oxidative flavonoid, has been researched since 2010. Results from animal and in-vitro studies, obtained from databases, also indicate that the use of phloretin in treating BPH and PCa is promising. Due to its effect on inflammatory cytokines, apoptosis or anti-apoptosis, reactive oxygen species, anti-oxidant enzymes and oxidative stress, phloretin is worthy of further study in human clinical trials regarding safety and effective dosages.
- Open Access
- 29 January 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-13
Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma
Mutations in the isocitrate dehydrogenase gene (IDH1) are involved in the progression of tumors. Although IDH1 has a role in various tumors, its clinical relevance and its expression in response to the immune response have not been investigated in prostate adenocarcinoma (PRAD). In the present study, we investigated the utility of IDH1 as a prognostic biomarker for PRAD by analyzing IDH1 mRNA expression and its association with patient survival and immune cell infiltration. IDH1 mRNA expression was significantly higher in PRAD tissue than in normal tissue, and Kaplan–Meier survival analysis showed that IDH1 expression was significantly associated with poor prognosis in PRAD patients. To elucidate the mechanisms involved, the correlation between IDH1 expression and the level of immune cell infiltration, in particular of immunosuppressive cells such as CD8+ T-cells, CD4+ T-cells, and macrophages, was further analyzed by single-cell RNA sequencing. We also screened a pharmacogenetic database for IDH1-specific drugs that inhibited high expression in PRAD. In the present study, we used a combination of databases to identify a significant correlation between IDH1 expression and cellular infiltration and to explain the mechanism by which IDH1 confers poor prognosis in PRAD, thus demonstrating the relevance of IDH1 expression as a prognostic biomarker with clinical utility in PRAD patients.
- 29 January 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-13
Open AccessIntegrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma
Mutations in the isocitrate dehydrogenase gene (IDH1) are involved in the progression of tumors. Although IDH1 has a role in various tumors, its clinical relevance and its expression in response to the immune response have not been investigated in prostate adenocarcinoma (PRAD). In the present study, we investigated the utility of IDH1 as a prognostic biomarker for PRAD by analyzing IDH1 mRNA expression and its association with patient survival and immune cell infiltration. IDH1 mRNA expression was significantly higher in PRAD tissue than in normal tissue, and Kaplan–Meier survival analysis showed that IDH1 expression was significantly associated with poor prognosis in PRAD patients. To elucidate the mechanisms involved, the correlation between IDH1 expression and the level of immune cell infiltration, in particular of immunosuppressive cells such as CD8+ T-cells, CD4+ T-cells, and macrophages, was further analyzed by single-cell RNA sequencing. We also screened a pharmacogenetic database for IDH1-specific drugs that inhibited high expression in PRAD. In the present study, we used a combination of databases to identify a significant correlation between IDH1 expression and cellular infiltration and to explain the mechanism by which IDH1 confers poor prognosis in PRAD, thus demonstrating the relevance of IDH1 expression as a prognostic biomarker with clinical utility in PRAD patients.
- Open Access
- 27 July 2021
- Published by Elsevier in Asian Journal of Surgery
- Vol. 44 (10) , 1291
A novel distal ureter management during robot-assisted nephroureterectomy with bladder cuff excision
- 27 July 2021
- Published by Elsevier in Asian Journal of Surgery
- Vol. 44 (10) , 1291
Open AccessA novel distal ureter management during robot-assisted nephroureterectomy with bladder cuff excision